Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene

C Iadecola, F Zhang, R Casey… - Journal of …, 1997 - Soc Neuroscience
C Iadecola, F Zhang, R Casey, M Nagayama, ME Ross
Journal of Neuroscience, 1997Soc Neuroscience
Inducible nitric oxide synthase (iNOS), an enzyme that produces toxic amounts of nitric
oxide, is expressed in a number of brain pathologies, including cerebral ischemia. We used
mice with a null mutation of the iNOS gene to study the role of iNOS in ischemic brain
damage. Focal cerebral ischemia was produced by occlusion of the middle cerebral artery
(MCA). In wild-type mice, iNOS mRNA expression in the post-ischemic brain begun between
24 and 48 hr peaked at 96 hr and subsided 7 d after MCA occlusion. iNOS mRNA induction …
Inducible nitric oxide synthase (iNOS), an enzyme that produces toxic amounts of nitric oxide, is expressed in a number of brain pathologies, including cerebral ischemia. We used mice with a null mutation of the iNOS gene to study the role of iNOS in ischemic brain damage. Focal cerebral ischemia was produced by occlusion of the middle cerebral artery (MCA). In wild-type mice, iNOS mRNA expression in the post-ischemic brain begun between 24 and 48 hr peaked at 96 hr and subsided 7 d after MCA occlusion. iNOS mRNA induction was associated with expression of iNOS protein and enzymatic activity. In contrast, mice lacking the iNOS gene did not express iNOS message or protein after MCA occlusion. The infarct and the motor deficits produced by MCA occlusion were smaller in iNOS knockouts than in wild-type mice (p < 0.05). Such reduction in ischemic damage and neurological deficits was observed 96 hr after ischemia but not at 24 hr, when iNOS is not yet expressed in wild-type mice. The decreased susceptibility to cerebral ischemia in iNOS knockouts could not be attributed to differences in the degree of ischemia or vascular reactivity between wild-type and knockout mice. These findings indicate that iNOS expression is one of the factors contributing to the expansion of the brain damage that occurs in the post-ischemic period. iNOS inhibition may provide a novel therapeutic strategy targeted specifically at the secondary progression of ischemic brain injury.
Soc Neuroscience